Welcome to our dedicated page for Aquestive Therapeutics news (Ticker: $AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aquestive Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aquestive Therapeutics's position in the market.
Aquestive Therapeutics (NASDAQ: AQST) has announced key executive appointments to boost its leadership team ahead of the anticipated launch of Anaphylm™ (epinephrine) Sublingual Film. Sherry Korczynski joins as Senior VP, Sales and Marketing, bringing over 20 years of experience, including roles at Mylan and ANI Pharmaceuticals. Dr. Stephen Wargacki is promoted to Chief Science Officer, having contributed significantly to the company's epinephrine prodrug platform since joining in 2015. Cassie Jung, with two decades at Aquestive, is named Chief Operating Officer, previously overseeing operations and CNS development. These strategic appointments aim to strengthen Aquestive's commercial capabilities and advance the launch of Anaphylm, potentially the first non-invasive epinephrine treatment for severe allergic reactions, pending FDA approval.
Aquestive Therapeutics will present data on Anaphylm™ (epinephrine) sublingual film at the 2024 Eastern Allergy Conference. The presentations will showcase positive pharmacokinetic and pharmacodynamic data from two clinical studies. The Phase 3 pivotal trial for Anaphylm met all expected endpoints, and the company plans to submit a New Drug Application to the FDA by the end of 2024. The conference will be held from May 30 to June 2 in Palm Beach, Florida, featuring experts in allergy, asthma, and immunology.
Aquestive's CEO Dan Barber expressed optimism about Anaphylm's potential to revolutionize severe allergic reaction treatments. The posters will be presented by Dr. Gary Slatko and Dr. David Golden on May 31.
Aquestive Therapeutics, Inc. (AQST) will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The management team will hold a fireside chat and host investor meetings. A webcast of the chat will be available on the company's website. For more information, visit investors.aquestive.com.
Aquestive Therapeutics reported positive results for their Phase 3 study on Anaphylm in Q1 2024, aiming for FDA approval by end of 2024. They also received FDA approval for Libervant for patients ages 2-5. The company extended their cash runway into 2026 through a public offering and continues to progress their pipeline development.
Aquestive Therapeutics has received U.S. FDA approval for Libervant™ (diazepam) Buccal Film for the treatment of seizure clusters in pediatric patients ages 2 to 5, making it the first and only FDA-approved orally administered rescue product for this indication. The company also announced immediate availability of various dosages of Libervant for this patient population. With this approval, Aquestive now has a total of 4 FDA approvals since 2018. Additionally, the company provided an update on its Anaphylm™ (epinephrine) Sublingual Film program, with a planned NDA submission by the end of 2024.
